Olmesartán/Amlodipino Krka (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil, the active ingredient in Olmesartán/Amlodipino Krka, is an angiotensin II receptor blocker (ARB) presented as a oral tablet for oral use. It treats hypertension, often in combination with other antihypertensive agents, and is intended for adults. GNH USA supplies Olmesartán/Amlodipino Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartán/Amlodipino Krka as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxomil/amlodipine is indicated for the management of high blood pressure, a key component of cardiovascular risk reduction.

- Hypertension: provides additive blood pressure reduction when used alone or with other antihypertensives. - Hypertension with isolated systolic hypertension: improves systolic control. - Hypertension in patients at high cardiovascular risk – helps to lower the risk of stroke and heart attack. - Hypertension – maintains long‑term blood‑pressure control. - Hypertension – offers once‑daily dosing convenience for patient adherence.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Peripheral edema - Headache - Dizziness - Flushing - Fatigue - Nausea

Serious or Rare Side Effects: - Angio‑angio angioedema - Severe hypotension - Hepatic dysfunction - Myocardial infarction in rare cases - Acute kidney injury - Severe allergic reactions

When prescribing Olmens ​   ​  ​  ​  ​  ​  ​   …  … … … … …

-     ... ... ... ... ... ... ...  … … … … ...  …  -  … … … … ... … … … ... … …